MARK GARRETSON: Open Payments
NPI 1538694617 · FAIRLAWN, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,928 in 148 payments from 12 companies in 2025. Trend: 2023 $3,465 · 2024 $3,542 · 2025 $3,928
Food & beverage: $3,813Consulting: $115
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 23 | $935 |
| E.R. Squibb & Sons, L.L.C. | 26 | $836 |
| Vanda Pharmaceuticals Inc. | 17 | $445 |
| ABBVIE INC. | 25 | $430 |
| Alkermes, Inc. | 16 | $386 |
| Otsuka America Pharmaceutical, Inc. | 10 | $217 |
| Lundbeck LLC | 15 | $201 |
| Supernus Pharmaceuticals, Inc. | 6 | $170 |
| Janssen Scientific Affairs, LLC | 1 | $115 |
| Janssen Pharmaceuticals, Inc | 3 | $76 |
Products named: CAPLYTA, COBENFY, FANAPT, VRAYLAR, REXULTI, LYBALVI, SPRAVATO, Qelbree.
Industry payments across OH — which companies pay providers there.
